REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Public ClinicalTrials.gov record NCT03185013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV-18.
Study identification
- NCT ID
- NCT03185013
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 201 participants
Conditions and interventions
Interventions
- VGX-3100 Biological
- Placebo Biological
- Electroporation (EP) Device
Biological · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2017 (Actual)
- Primary completion
- Jul 8, 2020 (Actual)
- Completion
- Apr 6, 2021 (Actual)
- Last update posted
- Jul 27, 2023
2017 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mesa Obstetricians and Gynecologist | Mesa | Arizona | 85209 | — |
| Women's Health Research | Scottsdale | Arizona | 85251 | — |
| Visions Clinical Research-Tucson | Tucson | Arizona | 85712 | — |
| Women's Medical Research Group | Clearwater | Florida | 33759 | — |
| Altus Research | Lake Worth | Florida | 33461 | — |
| Salom and Tangir LLC | Miramar | Florida | 33461 | — |
| Comprehensive Clinical Trials LLC | West Palm Beach | Florida | 33409 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Praetorian Pharmaceutical Research, LLC | Marrero | Louisiana | 70072 | — |
| Saginaw Valley Medical Research Group LLC | Saginaw | Michigan | 48604 | — |
| Meridian Clinical Research Norfolk | Norfolk | Nebraska | 68701 | — |
| New Jersey Medical School | Newark | New Jersey | 07103 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Suffolk Obstetrics and Gynecology | Port Jefferson | New York | 11777 | — |
| Lyndhurst Clinical Research | Winston-Salem | North Carolina | 27103 | — |
| Greenville Pharmaceutical Research, Inc. | Greenville | South Carolina | 29615 | — |
| Magnolia Ob/Gyn Research Center, LLC | Myrtle Beach | South Carolina | 29572 | — |
| Chattanooga Medical Research Inc | Chattanooga | Tennessee | 37404 | — |
| Women's Physician Group | Memphis | Tennessee | 38104 | — |
| UAG Innovation Women Research, LLC | Houston | Texas | 77074 | — |
| Group For Women | Norfolk | Virginia | 23502 | — |
| Eastern Virginia Medical School | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03185013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03185013 live on ClinicalTrials.gov.